Policy Notices

• AHRQ Guide Notice on Implementation of the Use of a Single Institutional Review Board (IRB) for Cooperative Research at 45 CFR 46.114 (b)
  (NOT-HS-20-005)
  Agency for Healthcare Research and Quality
  

General Notices

• Notice of Technical Assistance Webinar for NHLBI RFA-HL-21-011 "Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33)"
  (NOT-HL-20-748)
  National Heart, Lung, and Blood Institute
  

Notice of Changes to Funding Opportunities

• Notice of NIAAA Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"
  (NOT-AA-19-034)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of NIDA Participation in PAR-19-343, "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)"
  (NOT-DA-20-029)
  National Institute on Drug Abuse
  

• Notice of NIDCR Participation in PAR-19-373 "Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Clinical Trials Not Allowed)"
  (NOT-DE-20-004)
  National Institute of Dental and Craniofacial Research
  

• Notice of NIDCR Participation in PAR-19-384 "Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Basic Experimental Studies with Humans Required)"
  (NOT-DE-20-005)
  National Institute of Dental and Craniofacial Research
  

• Notice of Change: Emphasizing an Opportunity for New Institutional Applicants in Response to PAR-19-204 Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional) ________________________________________
  (NOT-HG-20-013)
  National Human Genome Research Institute
  

• Notice of Change in Expiration Date of PAR-17-338 "Continuation of Existing Grant Based Epidemiology Cohort Studies in Heart, Lung, Blood, and Sleep Diseases andDisorders (U01-Clinical Trials Not Allowed)"
  (NOT-HL-19-474)
  National Heart, Lung, and Blood Institute
  

• Addition of SBIR Direct-to-Phase II Program to NINDS RFA-NS-18-012, "Translational Neural Devices (U44 Clinical Trial Required)"
  (NOT-NS-20-034)
  National Institute of Neurological Disorders and Stroke
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
  (NOT-NS-20-032)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
  (NOT-NS-20-033)
  National Institute of Neurological Disorders and Stroke
  

Notices of Special Interest

• HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions.
  (NOT-AR-20-012)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  

• Notice of Special Interest (NOSI): De-implementation of Ineffective or Low-value Clinical Practices along the Cancer Care Continuum
  (NOT-CA-20-021)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Preclinical and Clinical Studies of the Interactions of Opioids and Stimulants
  (NOT-DA-20-007)
  National Institute on Drug Abuse
  

• Notice of Special Interest (NOSI): Biomarkers and Biotypes of Drug Addiction
  (NOT-DA-20-012)
  National Institute on Drug Abuse
  

• Notice of Special Interest: Administrative Supplements for Existing NIH Countermeasures Against Chemical Threats (CounterACT) Program Research Grants and Cooperative Agreement Awards
  (NOT-NS-20-029)
  National Institute of Neurological Disorders and Stroke
  National Eye Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  

• Notice of Special Interest: Administrative Supplements to Promote and Expand into the Research and Development of Medical Countermeasures Against Chemical Threats
  (NOT-NS-20-030)
  National Institute of Neurological Disorders and Stroke
  National Eye Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  

• Notice of Special Interest: Countermeasures Against Chemical Threats (CounterACT) U54 Centers of Excellence will only support targeted chemical threats of interest
  (NOT-NS-20-031)
  National Institute of Neurological Disorders and Stroke
  National Eye Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  

Funding Opportunities

• Development of Highly Innovative Tools and Technology for Analysis of Single Cells (STTR) (R41/R42 Clinical Trial Not Allowed)
  (PA-20-025)
  National Institute of Mental Health
  National Center for Advancing Translational Sciences
  National Eye Institute
  National Human Genome Research Institute
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.
  
  

• Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed)
  (PA-20-047)
  National Institute of Mental Health
  National Center for Advancing Translational Sciences
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.
  
  

• Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)
  (PAR-20-037)
  National Institute of Mental Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): Standard dates apply. The first standard application due date for this FOA is February 5, 2020
  
  

• Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)
  (PAR-20-038)
  National Institute of Mental Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): Standard dates apply The first standard application due date for this FOA is February 5, 2020.
  
  

• Enhancing Regulatory Science for Advancing Pharmaceutical Quality and Manufacturing (U01) Clinical Trials Optional
  (PAR-20-083)
  Food and Drug Administration
  Application Receipt Date(s): April 10, 2020, by 11:59 PM Eastern Time. April 3, 2021, by 11:59 PM Eastern Time. April 2, 2022, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
  

• NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
  (PAR-20-084)
  National Institute of Biomedical Imaging and Bioengineering
  Application Receipt Date(s): Standard dates apply.
  
  

• Pilot Centers for Precision Disease Modeling (U54)(Clinical Trials Not Allowed)
  (PAR-20-085)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): June 24, 2020
  
  

• Infrastructure for the Expansion of Rhesus macaque Colonies to Support HIV/AIDS-related Research (C06 Clinical Trial Not Allowed)
  (PAR-20-087)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): March 6, 2020. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Digital, Limited Interaction Trials and Epidemiology (D-LITE): Targeting HIV Incidence in the United States (U01 Clinical Trial Required)
  (RFA-AI-19-067)
  National Institute of Allergy and Infectious Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
  
  

• Radiobiology of High Linear Energy Transfer (High LET) Exposure in Cancer Treatment (R01, Clinical Trial Not Allowed)
  (RFA-CA-20-032)
  National Cancer Institute
  Application Receipt Date(s): March 19, 2020
  
  

• Center for Collaborative Research on Complex Generics (U18) Clinical Trials Optional
  (RFA-FD-20-007)
  Food and Drug Administration
  Application Receipt Date(s): April 13, 2020
  
  

• Renewal - Investigation of impact of manufacturing difference and formulation variation on drug release for Levonorgestrel Intrauterine System (U01) Clinical Trials Not Allowed
  (RFA-FD-20-020)
  Food and Drug Administration
  Application Receipt Date(s): New Date March 31, 2020, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
  

• Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed)
  (RFA-OD-20-002)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): January 07, 2023
  
  

• MoTrPAc Phase 2 Animal Studies (U01 Clinical Trial Not Allowed)
  (RFA-RM-20-009)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): March 20, 2020